Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
about
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerPhase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.Current treatment for ovarian cancer.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.Review of the use of topotecan in ovarian carcinoma.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerKey role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.Current treatment and clinical trials in ovarian cancer.Palliative chemotherapy for malignant ascites secondary to ovarian cancer.Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GISecond-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
P2860
Q28364213-17BAC0C0-1C9D-4498-92D7-8FE9B3A517F4Q33395064-D3B160A2-D288-448B-88ED-BC6E83AC562EQ33396185-C7BCB2C5-453D-4DAE-A2DA-D50940F89798Q34240764-E079EEBC-562E-4C76-B0FA-358E05F1E04EQ34616645-A7348D00-AFC8-4091-B6DA-E72F1801CADEQ34734502-0011A739-72FD-4660-B892-F54B1A0E0200Q35608564-9A76AE16-9EEA-4FDC-AA03-F68A090080E0Q35925538-A54201B9-6777-4C0F-98CE-3950FBC742D7Q36488198-4D080599-B250-4BBE-931F-27F306037F13Q36689071-F29EBF53-ED77-4D93-94DC-3DDC312BC7E1Q37123465-511D77B6-2FAA-4814-A105-066C21A3D8CEQ37159547-6F03E06B-6B21-4D9A-9F1D-B6DCFA410E52Q37724199-5D86F961-83F8-496E-800F-857D895085B8Q37987902-1F9FA277-BD8A-4B61-8664-EF60A2A83BA1Q40270631-33CEDA6C-592A-47CD-9476-71F32592F1E2Q43010573-DE6C17C4-F55E-4D24-974E-948EAD654043Q44117882-FC99171D-9072-4864-91B6-22017724B086Q44484573-3ADE0355-98BE-45C1-A8F4-000E11FEF797
P2860
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@ast
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@en
type
label
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@ast
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@en
prefLabel
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@ast
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@en
P2093
P356
P1433
P1476
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
@en
P2093
P304
P356
10.1006/GYNO.1997.4787
P407
P577
1997-09-01T00:00:00Z